Evaluation of a Novel H3 Antagonist, GT 2016, for Add

The long-term objectives are to develop novel histamine H3 receptor antagonists to increase wakefuland enhance cognitive abilities. The specific aims of this grant are (1) to test a novel non- thiourfor its ability to increase histamine release in various rat brain regions, including the frontal anhippocampus, corpus striatum and hypothalamus ; (2) to determine if GT-2016 possesses cognition-enhanormal juvenile and adult rats; (3) to produce an attention deficit disorder (ASS) juvenile rat pupcognitive impairments in this model; (4) to determine if GT-2016 reverses the cognitive deficits infirst aim will provide information on the regional specificity of GT-2016 on histamine turnover. Thedemonstrate the cognition enhancement of GT-2016 in juvenile and young adult normal rats. The thirdpostnatal intracisternal administration 6-OHDA, five days following birth, to produce a selective loneurons. These animals will be tested for hyperactivity and cognitive deficits and reversal of the ddetermined for GT-2016. Data generated from this research could identify the use of H3 antagonists icognitive disorders including ADD.